Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Fellowship Award - Priority Announcement: Fragile X (SHOPP)

McGill University

$67,500.00

Development of synaptic kainate receptors (KARs) in a mouse model of Fragile X Syndrome (FXS)

EF 2012-13

Résumé
Fragile X Syndrome (FXS) is the leading cause of inherited mental impairment. It is known to involve disturbances in the primary excitatory communication system in the brain, the glutamate signaling system. Glutamate communicates by acting at AMPA-type, NMDA-type, kainate-type and metabotropic glutamate receptors. Metabotropic glutamate receptors are promising therapeutic agents for the treatment of FXS. Interestingly, kainate-type receptors are currently the only main type of glutamate receptors that have not been examined in the pathophysiology and therapeutics of FXS. This study proposes to explore the expression and function of kainate-type receptors of Purkinje cells in the mouse cerebellum from birth to adulthood. In particular it will examine how kainate receptors regulate Purkinje cell activity by coupling to other ion channels and question whether this process is disrupted in a mouse model of FXS. Cerebellum Purkinje cells are known to use kainate-type receptors as part of their communication system and these cells are physiologically and physically disturbed in mouse models of FXS. By assigning a potential role for kainate-type receptors in FXS we will identify a novel therapeutic target for the treatment of FXS. To this end, metabotropic glutamate receptor drugs, known to be beneficial in FXS, and kainate-type receptor drugs will be tested alone or in combination to determine if they can correct the known and proposed deficits associated with FXS in cerebellum Purkinje cells.
Programme
Fellowship Award - Priority Announcement: Fragile X (SHOPP)
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
270547
Name
Daniels Bryan
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Fragile X Research Foundation of Canada
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Development of synaptic kainate receptors (KARs) in a mouse model of Fragile X Syndrome (FXS)
Programtype2
Fellowship Programs
Orgnameinp2
McGill University
Cihramount2
$67,500
Cihrequipment2
$0
Programname2
Fellowship Award - Priority Announcement: Fragile X (SHOPP)
Keyworddelim
Cerebellum; Development; Fragile X Syndrome; Ionotropic Glutamate Receptors; Kainate; Metabotropic Glutamate Receptors; Purkinje Cell
Abstract
Fragile X Syndrome (FXS) is the leading cause of inherited mental impairment. It is known to involve disturbances in the primary excitatory communication system in the brain, the glutamate signaling system. Glutamate communicates by acting at AMPA-type, NMDA-type, kainate-type and metabotropic glutamate receptors. Metabotropic glutamate receptors are promising therapeutic agents for the treatment of FXS. Interestingly, kainate-type receptors are currently the only main type of glutamate receptors that have not been examined in the pathophysiology and therapeutics of FXS. This study proposes to explore the expression and function of kainate-type receptors of Purkinje cells in the mouse cerebellum from birth to adulthood. In particular it will examine how kainate receptors regulate Purkinje cell activity by coupling to other ion channels and question whether this process is disrupted in a mouse model of FXS. Cerebellum Purkinje cells are known to use kainate-type receptors as part of their communication system and these cells are physiologically and physically disturbed in mouse models of FXS. By assigning a potential role for kainate-type receptors in FXS we will identify a novel therapeutic target for the treatment of FXS. To this end, metabotropic glutamate receptor drugs, known to be beneficial in FXS, and kainate-type receptor drugs will be tested alone or in combination to determine if they can correct the known and proposed deficits associated with FXS in cerebellum Purkinje cells.
Competitiondate
201210
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Daniels, Bryan
Approvedterm
3 ans 0 mois
Cihrcontribution2
SPIR~ $67,500~ $0~